XFOR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XF

Mkt Cap

$256.3M

Volume

899.89K

Next Earnings

November 4th

Loading chart

XF

XFORX4 Pharmaceuticals, Inc. Common Stock

XFOR

Pay with—

Available Balance0.00

XF

Mkt Cap

$261.7M

Volume

899.89K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM SyndromeX4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of mavorixafor (XOLREMDI) for treating WHIM syndrome in the EU. The drug, already FDA-approved in the U.S., would be the first and only therapy available in Europe for this ultra-rare immunodeficiency disorder. Final approval from the European Commission is anticipated in Q2 2026. X4 has partnered with Norgine for commercialization in Europe, Australia, and New Zealand, with potential milestone payments up to €226 million and royalties up to the mid-twenties.GlobeNewswire Inc. · Feb 27, 2026

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public OfferingX4 Pharmaceuticals announced a public offering of 45,860,000 shares and pre-funded warrants, expecting to raise approximately $135 million to fund Phase 3 development of mavorixafor for chronic neutropenic disorders.GlobeNewswire Inc. · Oct 24, 2025

Sitryx appoints Adam Mostafa as Chief Financial OfficerSitryx Therapeutics has appointed Adam Mostafa as its new Chief Financial Officer, bringing over 25 years of biotech financial experience, including previous roles at X4 Pharmaceuticals and Abpro Holdings.GlobeNewswire Inc. · Sep 8, 2025

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board LeadershipX4 Pharmaceuticals secured a $60 million PIPE financing led by Coastlands Capital, with significant management and board leadership changes, including new appointments of Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as CFO.GlobeNewswire Inc. · Aug 12, 2025

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)X4 Pharmaceuticals announced positive results from a six-month Phase 2 trial of its drug mavorixafor in treating chronic neutropenia. The drug durably increased participants' mean absolute neutrophil counts and enabled substantial reductions in G-CSF dosing while maintaining normal ANC levels.GlobeNewswire Inc. · Nov 13, 2024

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off dateGlobeNewswire Inc. · Jun 27, 2024

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 31, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 166,353 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.GlobeNewswire Inc. · Jun 3, 2024

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic NeutropeniaWebcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropenia Webcast to include interim hematological results from at least 15 trial participants and feature experts in the treatment of chronic neutropeniaGlobeNewswire Inc. · May 29, 2024

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility$125 million of non-dilutive capital extends projected cash runway into late 2025, excluding expected commercial sales from XOLREMDI™ (mavorixafor)GlobeNewswire Inc. · May 9, 2024

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesU.S. launch underway for XOLREMDI™ (mavorixafor) in WHIM syndromeGlobeNewswire Inc. · May 7, 2024

to start trading

XF

XFORX4 Pharmaceuticals, Inc. Common Stock

XFOR

Pay with—

Available Balance0.00

Your PositionYou don't own any XFOR yet.

Related Tickers

Earnings